Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key products include ORTHOVISC (osteoarthritis), AMVISC/AMVISC Plus (ophthalmic viscoelastic), HYVISC (equine osteoarthritis), INCERT (anti-adhesive), and ELEVESS (aesthetic dermatology). The company relies heavily on strategic partnerships for distribution, including Johnson & Johnson (DePuy Mitek) for U.S. ORTHOVISC sales and Bausch & Lomb for ophthalmic products.
Key Financial Metrics (Year Ended Dec 31, 2007)
| Metric | 2007 | 2006 |
|---|---|---|
| Total Revenue | $30.83 million | $26.84 million |
| Product Revenue | $26.91 million | $23.95 million |
| Licensing, Milestone & Contract Revenue | $3.92 million | $2.89 million |
| Net Income | $6.04 million | $4.60 million |
| Diluted EPS | $0.53 | $0.41 |
| Product Gross Margin | 56% | 54% |
| Cash, Cash Equivalents & Short-term Investments | $39.41 million | $47.17 million |
| Working Capital | $41.81 million | $52.15 million |
| Total Assets | $79.50 million | $68.11 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 15% to $30.83 million, driven primarily by a 20% increase in ORTHOVISC sales (up $2.26 million) and a $1.2 million one-time revenue recognition from the termination of the Galderma agreement.
- Product Mix Shifts:
- ORTHOVISC: U.S. sales surged 92% due to improved reimbursement codes and expanded sales force by DePuy Mitek. Conversely, international ORTHOVISC sales dropped 42% due to the elimination of government reimbursement in Turkey.
- Ophthalmic Products: Sales decreased 2% to $10.52 million, primarily due to inventory management adjustments by Bausch & Lomb.
- HYVISC: Sales increased 30% to $2.37 million.
- Operating Expenses: Total operating expenses rose 13% to $24.24 million. Selling, general, and administrative (SG&A) expenses increased 20% largely due to costs associated with the new Bedford, MA facility. R&D expenses increased 21% due to clinical trial costs and engineering for product scale-up.
- Capital Expenditures: Cash used in investing activities spiked to $18.28 million (from $1.31 million in 2006) due to the buildout of the new corporate headquarters and manufacturing facility.
Guidance, Outlook, Risks, and Unusual Items
- Facility Expansion: The company is building a new 134,000 sq. ft. facility in Bedford, MA, with a total projected cost of $30 million. Approximately $16.5 million was spent by year-end 2007. Manufacturing validation is expected by mid-2009.
- Financing: On January 31, 2008, Anika secured a $16 million unsecured revolving credit facility with Bank of America to fund the facility buildout. The facility converts to a term loan in 2009 with a maturity date of 2015.
- Product Pipeline:
- Monovisc: Received CE Mark approval in Oct 2007; expected launch in Europe mid-2008. U.S. clinical trials commenced Jan 2008.
- ELEVESS: Following the termination of the Galderma agreement in Nov 2007, Anika reacquired worldwide rights. The company intends to launch the product with a new partner or independently.
- Risks:
- Customer Concentration: Three customers accounted for 79% of product revenue in 2007. Bausch & Lomb and DePuy Mitek are critical partners.
- Regulatory: Significant risk regarding FDA and foreign regulatory approvals for new products (Monovisc, Cingal) and the re-qualification of the new manufacturing facility.
- Reimbursement: Continued volatility in international reimbursement policies, specifically the impact of the Turkish reimbursement change on ORTHOVISC sales.
Key Facts for Investor Verification
- Debt Covenants: Verify compliance with the new credit agreement covenants (quick ratio and fixed charge coverage ratio) given the significant capital expenditure program.
- Facility Timeline: Monitor the progress of the Bedford facility buildout and FDA validation, as delays could disrupt manufacturing or require maintaining two facilities simultaneously.
- ELEVESS Commercialization: Assess the company's ability to secure a new distribution partner or successfully self-distribute ELEVESS following the Galderma termination.
- International Recovery: Track the recovery of ORTHOVISC sales in Turkey and expansion into new international markets (China, India, Saudi Arabia) to offset the loss of reimbursement-driven sales.
- Deferred Revenue: Note the $16.2 million in deferred revenue related to the Johnson & Johnson agreement, which is recognized ratably over ten years, providing a stable but non-recurring revenue stream.